The vector of anti-BCMA chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human BCMA. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-BCMA antibody linked to OX40 and CD3ζ signaling domains. And the vector product was designed for the treatment of multiple myeloma.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|CAR-LC138||Anti-BCMA (C01_Rd4) h(41BB-CD3ζ) CAR, pCDCAR1|
|CAR-LC260||Anti-BCMA (C12A3.2) h(41BB-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC535||Lenti-BCMA CAR (scFv-41BB-CD3ζ, C11D5.3) Viral Particle|
|VP-CAR-LC623||Lenti-BCMA CAR (scFv-41BB-CD3ζ, COMBO_Rd4) Viral Particle|
|VP-CAR-LC536||Lenti-BCMA CAR (scFv-OX40-CD3ζ, C11D5.3) Viral Particle|
|VP-CAR-LC730||Lenti-BCMA CAR (scFv-41BB-CD3ζ, C12A3.2) Viral Particle|
|CAR-LC285||Anti-TNFRSF17 h(CD28-OX40-CD3ζ) Ligand-based CAR, pCDCAR1|
|CAR-LC041||Anti-BCMA (C12A3.2) h(CD28-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC510||Lenti-BCMA CAR (scFv-41BB-CD3ζ ) Viral Particle|
|CAR-LC043||Anti-BCMA (C11D5.3) h(41BB-CD3ζ) CAR, pCDCAR1|
Copyright © 2007 - 2019 Creative Biolabs. All Rights Reserved